Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against NuVasive, Inc.

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP announces that all purchasers of the securities of NuVasive, Inc. (“NuVasive” or the “Company”) NUVA between October 22, 2008 and July 30, 2013, inclusive (the “Class Period') have until October 28, 2013, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Southern District of California.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888) 773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER OR IF YOU PURCHASED NUVASIVE STOCK PRIOR TO THE CLASS PERIOD. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

The Complaint alleges that the Company issued false and/or misleading statements and failed to disclose that: (1) the Company improperly submitted false claims to Medicare and Medicaid in violation of federal and state laws and regulations; and (2) as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On July 30, 2013, the Company disclosed that it had received a federal administrative subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services in connection with an investigation into “possible false or otherwise improper claims submitted to Medicare and Medicaid.”

To learn more about this action or if you purchased NuVasive shares prior to the Class Period and have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.